Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study
Authors: Pugh, S.A., Bowers, M., Ball, A., Falk, S., Finch-Jones, M., Valle, J.W., O'Reilly, D.A., Siriwardena, A.K., Hornbuckle, J., Rees, M., Rees, C., Iveson, T., Hickish, T., Maishman, T., Stanton, L., Dixon, E., Corkhill, A., Radford, M., Garden, O.J., Cunningham, D., Maughan, T.S., Bridgewater, J.A., Primrose, J.N.
Journal: British Journal of Cancer
Publication Date: 09/08/2016
Volume: 115
Issue: 4
Pages: 420-424
eISSN: 1532-1827
ISSN: 0007-0920
DOI: 10.1038/bjc.2016.208
Abstract:Background:The addition of cetuximab (CTX) to perioperative chemotherapy (CT) for operable colorectal liver metastases resulted in a shorter progression-free survival. Details of disease progression are described to further inform the primary study outcome.Methods:A total of 257 KRAS wild-type patients were randomised to CT alone or CT with CTX. Data regarding sites and treatment of progressive disease were obtained for the 109 (CT n=48, CT and CTX n=61) patients with progressive disease at the cut-off date for analysis of November 2012.Results:The liver was the most frequent site of progression (CT 67% (32/48); CT and CTX 66% (40/61)). A higher proportion of patients in the CT and group had multiple sites of progressive disease (CT 8%, 4/48; CT and CTX 23%, 14/61 P=0.04). Further treatment for progressive disease is known for 84 patients of whom 69 received further CT, most frequently irinotecan based. Twenty-two patients, 11 in each arm, received CTX as a further line agent.Conclusions:Both the distribution of progressive disease and further treatment are as expected for such a cohort. The pattern of disease progression seen is consistent with failure of systemic micrometastatic disease control rather than failure of local disease control following liver surgery.
https://eprints.bournemouth.ac.uk/24880/
Source: Scopus
Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study.
Authors: Pugh, S.A., Bowers, M., Ball, A., Falk, S., Finch-Jones, M., Valle, J.W., O'Reilly, D.A., Siriwardena, A.K., Hornbuckle, J., Rees, M., Rees, C., Iveson, T., Hickish, T., Maishman, T., Stanton, L., Dixon, E., Corkhill, A., Radford, M., Garden, O.J., Cunningham, D., Maughan, T.S., Bridgewater, J.A., Primrose, J.N.
Journal: Br J Cancer
Publication Date: 09/08/2016
Volume: 115
Issue: 4
Pages: 420-424
eISSN: 1532-1827
DOI: 10.1038/bjc.2016.208
Abstract:BACKGROUND: The addition of cetuximab (CTX) to perioperative chemotherapy (CT) for operable colorectal liver metastases resulted in a shorter progression-free survival. Details of disease progression are described to further inform the primary study outcome. METHODS: A total of 257 KRAS wild-type patients were randomised to CT alone or CT with CTX. Data regarding sites and treatment of progressive disease were obtained for the 109 (CT n=48, CT and CTX n=61) patients with progressive disease at the cut-off date for analysis of November 2012. RESULTS: The liver was the most frequent site of progression (CT 67% (32/48); CT and CTX 66% (40/61)). A higher proportion of patients in the CT and group had multiple sites of progressive disease (CT 8%, 4/48; CT and CTX 23%, 14/61 P=0.04). Further treatment for progressive disease is known for 84 patients of whom 69 received further CT, most frequently irinotecan based. Twenty-two patients, 11 in each arm, received CTX as a further line agent. CONCLUSIONS: Both the distribution of progressive disease and further treatment are as expected for such a cohort. The pattern of disease progression seen is consistent with failure of systemic micrometastatic disease control rather than failure of local disease control following liver surgery.
https://eprints.bournemouth.ac.uk/24880/
Source: PubMed
Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study
Authors: Pugh, S.A., Bowers, M., Ball, A., Falk, S., Finch-Jones, M., Valle, J.W., O'Reilly, D.A., Siriwardena, A.K., Hornbuckle, J., Rees, M., Rees, C., Iveson, T., Hickish, T., Maishman, T., Stanton, L., Dixon, E., Corkhill, A., Radford, M., Garden, O.J., Cunningham, D., Maughan, T.S., Bridgewater, J.A., Primrose, J.N.
Journal: BRITISH JOURNAL OF CANCER
Publication Date: 09/08/2016
Volume: 115
Issue: 4
Pages: 420-424
eISSN: 1532-1827
ISSN: 0007-0920
DOI: 10.1038/bjc.2016.208
https://eprints.bournemouth.ac.uk/24880/
Source: Web of Science
Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study
Authors: Pugh, S.A., Bowers, M., Ball, A., Falk, S., Finch-Jones, M., Valle, J.W., O'Reilly, D.A., Siriwardena, A.K., Hornbuckle, J., Rees, M., Rees, C., Iveson, T., Hickish, T., Maishman, T., Stanton, L., Dixon, E., Corkhill, A., Radford, M., Garden, O.J., Cunningham, D., Maughan, T.S., Bridgewater, J.A., Primrose, J.N.
Journal: British Journal of Cancer
Publication Date: 09/08/2016
Volume: 115
Issue: 4
Pages: 420-424
eISSN: 1532-1827
ISSN: 0007-0920
DOI: 10.1038/bjc.2016.208
Abstract:Background:The addition of cetuximab (CTX) to perioperative chemotherapy (CT) for operable colorectal liver metastases resulted in a shorter progression-free survival. Details of disease progression are described to further inform the primary study outcome.Methods:A total of 257 KRAS wild-type patients were randomised to CT alone or CT with CTX. Data regarding sites and treatment of progressive disease were obtained for the 109 (CT n=48, CT and CTX n=61) patients with progressive disease at the cut-off date for analysis of November 2012.Results:The liver was the most frequent site of progression (CT 67% (32/48); CT and CTX 66% (40/61)). A higher proportion of patients in the CT and group had multiple sites of progressive disease (CT 8%, 4/48; CT and CTX 23%, 14/61 P=0.04). Further treatment for progressive disease is known for 84 patients of whom 69 received further CT, most frequently irinotecan based. Twenty-two patients, 11 in each arm, received CTX as a further line agent.Conclusions:Both the distribution of progressive disease and further treatment are as expected for such a cohort. The pattern of disease progression seen is consistent with failure of systemic micrometastatic disease control rather than failure of local disease control following liver surgery.
https://eprints.bournemouth.ac.uk/24880/
Source: Manual
Preferred by: Tamas Hickish
Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study.
Authors: Pugh, S.A., Bowers, M., Ball, A., Falk, S., Finch-Jones, M., Valle, J.W., O'Reilly, D.A., Siriwardena, A.K., Hornbuckle, J., Rees, M., Rees, C., Iveson, T., Hickish, T., Maishman, T., Stanton, L., Dixon, E., Corkhill, A., Radford, M., Garden, O.J., Cunningham, D., Maughan, T.S., Bridgewater, J.A., Primrose, J.N.
Journal: British journal of cancer
Publication Date: 08/2016
Volume: 115
Issue: 4
Pages: 420-424
eISSN: 1532-1827
ISSN: 0007-0920
DOI: 10.1038/bjc.2016.208
Abstract:Background
The addition of cetuximab (CTX) to perioperative chemotherapy (CT) for operable colorectal liver metastases resulted in a shorter progression-free survival. Details of disease progression are described to further inform the primary study outcome.Methods
A total of 257 KRAS wild-type patients were randomised to CT alone or CT with CTX. Data regarding sites and treatment of progressive disease were obtained for the 109 (CT n=48, CT and CTX n=61) patients with progressive disease at the cut-off date for analysis of November 2012.Results
The liver was the most frequent site of progression (CT 67% (32/48); CT and CTX 66% (40/61)). A higher proportion of patients in the CT and group had multiple sites of progressive disease (CT 8%, 4/48; CT and CTX 23%, 14/61 P=0.04). Further treatment for progressive disease is known for 84 patients of whom 69 received further CT, most frequently irinotecan based. Twenty-two patients, 11 in each arm, received CTX as a further line agent.Conclusions
Both the distribution of progressive disease and further treatment are as expected for such a cohort. The pattern of disease progression seen is consistent with failure of systemic micrometastatic disease control rather than failure of local disease control following liver surgery.https://eprints.bournemouth.ac.uk/24880/
Source: Europe PubMed Central